StocksMedium•14 October 2026•
1 min read
Entrada Therapeutics Reports Positive Phase 1/2 DMD Trial Data
Key Facts
1Entrada Therapeutics announced that Cohort 1 met primary safety and tolerability objectives in the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45.
2Results showed a 0.10% mean increase in dystrophin production in treated participants at the initial dose of 5 mg/kg.
3Cohort 2 enrollment is complete, and the company expects to report data for the 10 mg/kg dose in the first half of 2027.
Entrada Therapeutics announced that Cohort 1 of its Phase 1/2 ELEVATE-45-201 study for ENTR-601-45 met its primary safety and tolerability objectives. GlobeNewswire reported that results showed a 0.10% mean increase in dystrophin production among participants treated with an initial dose of 5 mg/kg.
TRDA closed at $4.86 on October 13, 2026, prior to the release of this clinical data. The company confirmed that enrollment for Cohort 2 is complete and expects to report data for the higher 10 mg/kg dose in the first half of 2027.